JAX humanized NSG mice represent an innovative and cost-effective platform to stimulate trials, evaluate multiple drugs alone or in combination, and produce reliable predicative data. Explore our collection of humanized mice resources and learn how this innovative platform models immunity to study and evaluate treatments for a variety of human diseases.
Join us as we discuss a collaborative effort between academia and a biopharmaceutical company, which utilized humanized mice to explore the role of mast cells in the melanoma tumor microenvironment.
Watch Video
In this PubCast, we discuss a study from Yale University that employed humanized PBMC-NSG mice to model HIV and test the efficacy of two novel long-acting antiretroviral delivery systems. Resource
Watch Video
February 20, 2024 - During this presentation, we compare strategies for immune humanization of NSG variants to support translatable preclinical immunology and oncology research.
Watch Video
January 16, 2024 - In this webinar, we discuss the most widely used immunodeficient mouse models and essential considerations for selecting the most appropriate model.
Watch Video
During this webinar, we discuss preclinical data showcasing efficacy and safety testing of immunotherapies in immune humanized mouse models.
Watch Video
In this webinar, we discuss the humanized FcRn platform, an effective tool that provides relevant PK data for candidate therapeutic antibodies and albumin-conjugated molecules.
Watch Video
In this webinar, we will introduce two new enhanced NSG models developed at The Jackson Laboratory: NSG-SGM3-IL15 and NSG-FLT3.
Watch Video
Learn about Hu-PBMC NSG models that can be used to test the efficacy of human T cell immunomodulatory therapeutics for graft-versus-host disease (GvHD), autoimmune disorders, and cancer.
Watch Video
Leading this presentation is guest speaker Dr. Timothy Cripe from Nationwide Children’s Hospital and The Ohio State University.
Watch Video
Using lentiviral shRNA constructs, this presentation demonstrates that DROSHA, but not DICER, is required for the differentiation of human HSCs after engraftment into immunodeficient NSG-SGM3 mice.
Watch Video
Ashwin Ajith Ph.D., a postdoctoral fellow at the Georgia Cancer Center, Augusta University, discusses using humanized mouse models to study alloimmune responsiveness between donor and recipients.
Watch Video
Meenard Herlyn, DVM, DSc discusses the development of a variety of 3D models, from human skin equivalents to organoids, mimicking cellular interactions in normal and malignant tissues.
Watch Video
The most common type of breast cancer is estrogen receptor-positive (ER+). ER+ tumors can be successfully treated with hormone therapy, but many tumors acquire endocrine resistance which limits treatm
Watch Video
This discussion focuses on preclinical efficacy and safety testing for novel antibody-based therapeutics.
Watch Video
CRISPR/Cas9 can quickly generate new translational mouse models directly on the genetic background needed for your preclinical research. This saves valuable research time by reducing the need for...
Learn More
Hong Zheng, M.D., Ph.D., Associate Professor of Medicine at Penn State Cancer Institute, Penn State University College of Medicine joined us to lead a discussion on a new immune-humanized mouse model.
Watch Video
This whitepaper examines the constraints and challenges inherent in each CAR T study type and how to overcome them with in vivo studies using fully humanized mouse models.
Read Flipbook
Read Flipbook
JAX NSG-MHC I/II KO mice readily engraft tumors and human PBMCs, have delayed GvHD, and deliver translationally-relevant results for various research applications.
Read Flipbook
Review JAX’s CRS evaluation capabilities and see how a CRS study can help move your CAR T therapeutic into the clinic faster, safer, and more confidently.
Read Flipbook
Loading More...
